307 related articles for article (PubMed ID: 34688130)
1. Synthesis of a new series of pyrazolo[1,5-a]pyrimidines as CDK2 inhibitors and anti-leukemia.
Almehmadi SJ; Alsaedi AMR; Harras MF; Farghaly TA
Bioorg Chem; 2021 Dec; 117():105431. PubMed ID: 34688130
[TBL] [Abstract][Full Text] [Related]
2. Novel Pyrazolo[3,4-d]pyrimidines as Potential Cytotoxic Agents: Design, Synthesis, Molecular Docking and CDK2 Inhibition.
Maher M; Kassab AE; Zaher AF; Mahmoud Z
Anticancer Agents Med Chem; 2019; 19(11):1368-1381. PubMed ID: 31038080
[TBL] [Abstract][Full Text] [Related]
3. Molecular docking approach for the design and synthesis of new pyrazolopyrimidine analogs of roscovitine as potential CDK2 inhibitors endowed with pronounced anticancer activity.
Hamed OA; Abou-Elmagd El-Sayed N; Mahmoud WR; F Elmasry G
Bioorg Chem; 2024 Jun; 147():107413. PubMed ID: 38696844
[TBL] [Abstract][Full Text] [Related]
4. Synthesis, EGFR Inhibition and Anti-cancer Activity of New 3,6-dimethyl-1-phenyl-4-(substituted-methoxy)pyrazolo[3,4-d] pyrimidine Derivatives.
Bakr RB; Mehany ABM; Abdellatif KRA
Anticancer Agents Med Chem; 2017; 17(10):1389-1400. PubMed ID: 28270084
[TBL] [Abstract][Full Text] [Related]
5. Synthesis, anticancer evaluation, and molecular docking studies of some novel 4,6-disubstituted pyrazolo[3,4-d]pyrimidines as cyclin-dependent kinase 2 (CDK2) inhibitors.
Cherukupalli S; Chandrasekaran B; Kryštof V; Aleti RR; Sayyad N; Merugu SR; Kushwaha ND; Karpoormath R
Bioorg Chem; 2018 Sep; 79():46-59. PubMed ID: 29753773
[TBL] [Abstract][Full Text] [Related]
6. Design, Synthesis, biological Evaluation, and molecular docking studies of novel Pyrazolo[3,4-d]Pyrimidine derivative scaffolds as potent EGFR inhibitors and cell apoptosis inducers.
Sherbiny FF; Bayoumi AH; El-Morsy AM; Sobhy M; Hagras M
Bioorg Chem; 2021 Nov; 116():105325. PubMed ID: 34507234
[TBL] [Abstract][Full Text] [Related]
7. Design, synthesis and biological evaluation of certain CDK2 inhibitors based on pyrazole and pyrazolo[1,5-a] pyrimidine scaffold with apoptotic activity.
Ali GME; Ibrahim DA; Elmetwali AM; Ismail NSM
Bioorg Chem; 2019 May; 86():1-14. PubMed ID: 30682722
[TBL] [Abstract][Full Text] [Related]
8. Discovery of New Pyrazolopyridine, Furopyridine, and Pyridine Derivatives as CDK2 Inhibitors: Design, Synthesis, Docking Studies, and Anti-Proliferative Activity.
Abdel-Rahman AA; Shaban AKF; Nassar IF; El-Kady DS; Ismail NSM; Mahmoud SF; Awad HM; El-Sayed WA
Molecules; 2021 Jun; 26(13):. PubMed ID: 34206976
[TBL] [Abstract][Full Text] [Related]
9. Design, synthesis, and biological evaluation of dinaciclib and CAN508 hybrids as CDK inhibitors.
Odeh DM; Allam HA; Baselious F; Mahmoud WR; Odeh MM; Ibrahim HS; Abdel-Aziz HA; Mohammed ER
Drug Dev Res; 2024 May; 85(3):e22193. PubMed ID: 38685605
[TBL] [Abstract][Full Text] [Related]
10. Mechanistic selectivity investigation and 2D-QSAR study of some new antiproliferative pyrazoles and pyrazolopyridines as potential CDK2 inhibitors.
Hassan GS; Georgey HH; Mohammed EZ; George RF; Mahmoud WR; Omar FA
Eur J Med Chem; 2021 Jun; 218():113389. PubMed ID: 33784602
[TBL] [Abstract][Full Text] [Related]
11. Novel pyrazolopyrimidines: Synthesis, in vitro cytotoxic activity and mechanistic investigation.
Hassan GS; Abdel Rahman DE; Nissan YM; Abdelmajeed EA; Abdelghany TM
Eur J Med Chem; 2017 Sep; 138():565-576. PubMed ID: 28704759
[TBL] [Abstract][Full Text] [Related]
12. Design, synthesis and antitumor evaluation of novel 5-methylpyrazolo[1,5-a]pyrimidine derivatives as potential c-Met inhibitors.
Luo G; Ma Y; Liang X; Xie G; Luo Y; Zha D; Wang S; Yu L; Zheng X; Wu W; Zhang C
Bioorg Chem; 2020 Nov; 104():104356. PubMed ID: 33142417
[TBL] [Abstract][Full Text] [Related]
13. Tyrosine kinase inhibition effects of novel Pyrazolo[1,5-a]pyrimidines and Pyrido[2,3-d]pyrimidines ligand: Synthesis, biological screening and molecular modeling studies.
El Sayed MT; Hussein HAR; Elebiary NM; Hassan GS; Elmessery SM; Elsheakh AR; Nayel M; Abdel-Aziz HA
Bioorg Chem; 2018 Aug; 78():312-323. PubMed ID: 29625271
[TBL] [Abstract][Full Text] [Related]
14. Pyrazolo[3,4-d]pyrimidine-based dual EGFR T790M/HER2 inhibitors: Design, synthesis, structure-activity relationship and biological activity as potential antitumor and anticonvulsant agents.
Lamie PF; El-Kalaawy AM; Abdel Latif NS; Rashed LA; Philoppes JN
Eur J Med Chem; 2021 Mar; 214():113222. PubMed ID: 33545637
[TBL] [Abstract][Full Text] [Related]
15. Discovery of 4-amino-1H-pyrazolo[3,4-d]pyrimidin derivatives as novel discoidin domain receptor 1 (DDR1) inhibitors.
Dong R; Zhou X; Wang M; Li W; Zhang JY; Zheng X; Tang KX; Sun LP
Bioorg Med Chem; 2021 Jan; 29():115876. PubMed ID: 33246255
[TBL] [Abstract][Full Text] [Related]
16. Synthesis, biological evaluation, and
Mandour AA; Nassar IF; Abdel Aal MT; Shahin MAE; El-Sayed WA; Hegazy M; Yehia AM; Ismail A; Hagras M; Elkaeed EB; Refaat HM; Ismail NSM
J Enzyme Inhib Med Chem; 2022 Dec; 37(1):1957-1973. PubMed ID: 35815597
[TBL] [Abstract][Full Text] [Related]
17. Eco-friendly sequential one-pot synthesis, molecular docking, and anticancer evaluation of arylidene-hydrazinyl-thiazole derivatives as CDK2 inhibitors.
El-Naggar AM; El-Hashash MA; Elkaeed EB
Bioorg Chem; 2021 Mar; 108():104615. PubMed ID: 33484942
[TBL] [Abstract][Full Text] [Related]
18. New thiazol-hydrazono-coumarin hybrids targeting human cervical cancer cells: Synthesis, CDK2 inhibition, QSAR and molecular docking studies.
Abd El-Karim SS; Syam YM; El Kerdawy AM; Abdelghany TM
Bioorg Chem; 2019 May; 86():80-96. PubMed ID: 30685646
[TBL] [Abstract][Full Text] [Related]
19. Development of pyrolo[2,3-c]pyrazole, pyrolo[2,3-d]pyrimidine and their bioisosteres as novel CDK2 inhibitors with potent in vitro apoptotic anti-proliferative activity: Synthesis, biological evaluation and molecular dynamics investigations.
Azmy EM; Hagras M; Ewida MA; Doghish AS; Gamil Khidr E; El-Husseiny AA; Gomaa MH; Refaat HM; Ismail NSM; Nassar IF; Lashin WH
Bioorg Chem; 2023 Oct; 139():106729. PubMed ID: 37467621
[TBL] [Abstract][Full Text] [Related]
20. Novel pyrazolo[3,4-d]pyrimidines: design, synthesis, anticancer activity, dual EGFR/ErbB2 receptor tyrosine kinases inhibitory activity, effects on cell cycle profile and caspase-3-mediated apoptosis.
Maher M; Kassab AE; Zaher AF; Mahmoud Z
J Enzyme Inhib Med Chem; 2019 Dec; 34(1):532-546. PubMed ID: 30688116
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
